Inactivated hepatitis A vaccine: long-term antibody persistence

Vaccine
G WiedermannA Delem

Abstract

During the clinical development of safe, well tolerated and immunogenic vaccines against hepatitis A the persistence of protective antibodies was estimated, based on relatively short observation periods of 18 months to 3 years. We report here on longterm persistence of antibodies in volunteers who participated in one of the early clinical trials on inactivated hepatitis A candidate vaccines. In a randomized trial three groups of altogether 110 healthy adults, initially hepatitis A virus (HAV) seronegative persons were vaccinated with an inactivated hepatitis A vaccine according to the schedule 0-1-2-12 months. One group received 180 ELISA units, one group 360, and one 720 ELISA units per dose. Blood samples were taken prior to the first vaccination and at months 1, 2, 3, 4, 6, 12, 13, 18, 24, 36 and 84. The decrease of antibodies was characterized by two disappearance rates: a rapidly decreasing component and a slower decreasing one becoming predominant ca 12 months after booster vaccination. The disappearance of antibodies could be described by a two-component model which holds for t > or = 13 months. The estimated disappearance rates for the slow component (annual decrease) was found to be 11 and 13% for the 180 and 360 El. U...Continue Reading

References

Jan 1, 1992·Vaccine·G WiedermannA Safary
May 1, 1992·Journal of Immunotherapy·D R Anderson, R E McCoobery
Mar 25, 1991·Annals of Internal Medicine·M H SjogrenW Lednar
Jul 1, 1995·Journal of Medical Virology·C GoilavA Zuckerman
Jan 1, 1993·Vaccine·V PellegriniA J Zuckerman

❮ Previous
Next ❯

Citations

Dec 29, 2000·Journal of Medical Virology·K Van Herck, P Van Damme
Oct 12, 2002·Journal of Medical Virology·P A BovierC Herzog
Mar 17, 2000·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·M ArslanN N Zein
Nov 6, 2004·Current Treatment Options in Gastroenterology·Miguel R Arguedas, Michael B Fallon
Mar 23, 2004·Journal of the American Academy of Dermatology·Jashin J WuStephen K Tyring
Jun 10, 1998·Lancet·R S Koff
Mar 15, 2000·Vaccine·F AmbroschS Thoelen
Feb 27, 2003·Journal of Paediatrics and Child Health·C R MacIntyreP B McIntyre
May 25, 2011·The Journal of Infectious Diseases·Nancy F Crum-CianfloneUNKNOWN Infectious Disease Clinical Research Program HIV Working Group
Oct 11, 2003·The Pediatric Infectious Disease Journal·R Jake JacobsAllen S Meyerhoff
Dec 31, 2008·World Journal of Gastroenterology : WJG·Jameela AlkhalidiGuy W Neff
Aug 24, 2013·Hepatitis Monthly·Abbas Taghavi ArdakaniMostafa Haji Rezaei
Apr 13, 2000·Pediatric Clinics of North America·S MalayL I Lutwick
Jun 21, 2007·Microbiology and Immunology·Motoharu AbeYoichiro Kino
May 23, 2012·Vaccine·Jördis Jennifer OttSteven Todd Wiersma
Aug 11, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·R Jake JacobsAllen S Meyerhoff
Nov 8, 2005·The American Journal of Medicine·Jeffrey P Davis
Feb 22, 2001·Journal of Travel Medicine·C D Ericsson
Feb 22, 2001·Journal of Travel Medicine·R Steffen
Mar 11, 2017·Human Vaccines & Immunotherapeutics·Pierre Van DammeOlivier Van Der Meeren
Jan 9, 2004·Expert Review of Vaccines·Matthew G Deneke, Miguel R Arguedas
Feb 28, 2002·The American Journal of Gastroenterology·R Jake JacobsAllen S Meyerhoff
Jul 31, 2012·International Journal of STD & AIDS·S KourkountiA Katsambas
Jul 13, 2012·The Cochrane Database of Systematic Reviews·Greg J IrvingDaniel Pope
Apr 28, 2004·Journal of Travel Medicine·Gerhard Wiedermann

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.